EV/EBITDA Multiple: Soleno (SLNO)

Corporate company logo of soleno.life (SLNO)

DCCR approval will grant Soleno Therapeutics (SLNO) absolute pricing power due to highly inelastic demand. The company's EV/EBITDA ratio on the financial timeline confirms this trend, where the 28.06 mark serves as the current metric. A patent monopoly within the orphan disease niche guarantees high margins, while business success depends on clinical outcomes rather than market cycles.

SLNO (Soleno Therapeutics Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 05/30/2026

Soleno Therapeutics Inc (SLNO) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:SLNO (Soleno Therapeutics)
Product sample of Soleno Therapeutics, Inc.

Soleno Therapeutics (SLNO) focuses its highly specialized staff on the commercialization of a drug for the treatment of rare metabolic disorders. By analyzing the EV/EBITDA debt and operating leverage metric, an investor compares the total enterprise value with its earnings before depreciation and interest, which allows for an assessment of real market demand for the asset and the risk of overpayment during periods of rate volatility.

Who Soleno Therapeutics competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (Amicus Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio.com ETNB|Agios Corp (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Corp|Enterprise Value to EBITDA Ratio Altimmune Corp (ALT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aardvarktherapeutics.com (AARD)|Enterprise Value to EBITDA Ratio sagimet.com SGMT|EV/EBITDA Multiple BIOA (BioAge)|Biomea Fusion - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation